Search Results

You are looking at 1 - 10 of 59 items for :

  • "Thyroid carcinoma" x
Clear All
Full access

R. Michael Tuttle, Douglas W. Ball, David Byrd, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith C. McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang and Lori J. Wirth

approximately 0.1% per year beginning in early life, but at a much higher rate (∼2% per year) after exposure to head and neck irradiation. 5 , 6 By contrast, thyroid carcinoma is uncommon. For the United States population, the lifetime risk of being diagnosed

Full access

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann and Miranda Hughes

main histologic types of thyroid carcinoma include 1) differentiated, which includes papillary, follicular, and Hürthle cell carcinoma; 2) medullary carcinoma; and 3) anaplastic carcinoma (which is an aggressive undifferentiated tumor). An average of 58

Full access

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann and Miranda Hughes

, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Thyroid Carcinoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Thyroid Carcinoma

Full access

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann and Lisa A. Gurski

: December 10, 2018; Expiration date: December 10, 2019 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Thyroid Carcinoma Describe the rationale

Full access

Jeffrey F. Moley

Medullary Thyroid Carcinoma Medullary thyroid carcinoma (MTC) comprises 3% to 9% of all thyroid cancers and arises from thyroid C cells. MTC has several distinctive features. First, MTC may be sporadic (75% of cases) or hereditary, occurring

Full access

Maria A. Kouvaraki, Suzanne E. Shapiro, Jeffrey E. Lee, Douglas B. Evans and Nancy D. Perrier

therapy for papillary and follicular thyroid cancer . J Clin Endocrinol Metab 2001 ; 86 : 1447 – 1463 . 3 Hay ID Thompson GB Grant CS . Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in

Full access

H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida

Although thyroid carcinoma is relatively uncommon, approximately 33,550 new cases will be diagnosed in the United States in 2007. It occurs 2 to 3 times more often in women than in men, and with the incidence increasing by 4% per year, it is currently the eighth most common malignancy diagnosed in women. Although it occurs more often in women, mortality rates are higher for men, probably because they are usually older at the time of diagnosis (65–69 years vs. 50–54 years in women). Interestingly, the incidence of thyroid carcinoma increased almost 240% between 1950 and 2000, but mortality rates decreased more than 44%. Important updates to the 2007 guidelines include revised criteria for categorizing disease, revised recommendation for thyroid-stimulating hormone–stimulated thyroglobulin in some cases, and expanded CT recommendations for anaplastic carcinoma.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Stephanie L. Lee

the small risk for second primary malignancy in patients with stage II thyroid carcinoma, but patients should be counseled that the risks for this occurrence, especially leukemia, are low but are still a real risk associated with RAI therapy

Full access

Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon and Danny Rischin

effective treatments available. For tumors that harbor known targetable mutations, treatments directed at those mutations can be highly effective and well tolerated. 1 , 2 Anaplastic thyroid carcinoma (ATC) is an uncommon, highly aggressive tumor with a

Full access

R. Michael Tuttle and R. Leboeuf

HR . A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments] . Cancer 1998 ; 83 : 2638 – 2648 . 3. Patel KN Shaha AR . Poorly differentiated and anaplastic thyroid cancer